UBS Group
LKFT

UBS Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

UBS Group’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,400
Closed -$131K – 7957
2017
Q4 		$131K Buy
+1,400
New +$132K ﹤0.01% 5195

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group's LKFT Position: Q1 2026 in Review

UBS Group reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 50% in Q1 2026, selling an estimated $5.77M and leaving 175,289 shares worth $5.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4036.

UBS Group first reported a position in LKFT in Q2 2015 and has held it in 44 quarters since. The position peaked at $11.4M in Q4 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • UBS Group held 175,289 shares of Lakefront Biotherapeutics American Depositary Shares worth $5.26M as of Q1 2026.
  • UBS Group sold 174,155 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $5.77M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4036 holding.
  • UBS Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 44 quarters since.
  • UBS Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $11.4M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.